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Abstract: To overcome bacterial resistances, the need for
novel antimicrobial agents is urgent. The class of so-called
nucleoside antibiotics furnishes promising candidates for the
development of new antibiotics, as these compounds block
a clinically unexploited bacterial target: the integral mem-
brane protein MraY, a key enzyme in cell wall (peptidogly-
can) biosynthesis. Nucleoside antibiotics exhibit remarkable
structural diversity besides their uridine-derived core motifs.
Some sub-classes also show specific selectivities towards dif-
ferent Gram-positive and Gram-negative bacteria, which are
poorly understood so far. Herein, the synthesis of a novel
hybrid structure is reported, derived from the 5’-defunction-
alized uridine core moiety of muraymycins and the peptide
chain of sansanmycin B, as a new scaffold for the develop-
ment of antimicrobial agents. The reported muraymycin–
sansanmycin hybrid scaffold showed nanomolar activity
against the bacterial target enzyme MraY, but displayed no
significant antibacterial activity against S. aureus, E. coli, and
P. aeruginosa.
Introduction
With the rise of bacterial strains exhibiting resistance against
established antibiotics, novel drug candidates are urgently
needed for the future treatment of microbial infections.[1] Cell
wall (i.e. , peptidoglycan) biosynthesis is one typical bacterial
pathway targeted by many established antibiotics.[2] However,
nucleoside antibiotics are a promising class for the develop-
ment of new therapeutics as they block a clinically unexploited
target protein (MraY) involved in the membrane-associated
stages of peptidoglycan biosynthesis. By the inhibition of MraY
(translocase I), nucleoside antibiotics prevent the formation of
lipid I 3 as a key intermediate of bacterial cell wall formation
(Scheme 1). MraY is a membrane protein consisting of ten
transmembrane helices and five cytosolic loops.[3] It catalyzes
the transfer of UDP-MurNAc pentapeptide 1 (’Park’s nucleo-
tide’) to the membrane-bound lipid carrier undecaprenyl phos-
phate 2, thus yielding membrane-associated lipid I 3.[4]
Uridine-derived nucleoside antibiotics all share MraY as their
primary biological target, but are divided into structurally vary-
ing sub-classes, for example, muraymycins, mureidomycins,
sansanmycins, caprazamycins, tunicamycins, and others.[5] De-
spite this similar mode of action, their antimicrobial activities
differ significantly.[6] For instance, the pronounced activities of
mureidomycins, sansanmycins, and their related classes against
the Gram-negative ESKAPE pathogen P. aeruginosa distin-
guishes them from most other nucleoside antibiotics, including
muraymycins, which are mainly active against Gram-positive
pathogens.[7] Caprazamycins also display some limited anti-
Pseudomonas activity, but primarily good activity against
Gram-positive bacteria and M. tuberculosis. These pronounced
differences in the antibacterial activities of different sub-classes
of nucleoside antibiotics are only scarcely studied and there-
fore not well understood.
In the case of muraymycins, 19 naturally occurring conge-
ners were originally isolated from a Streptomyces sp. in 2002.[5a]
Scheme 1. MraY-catalyzed membrane-associated formation of lipid I 3
(membrane not shown). UDP = uridine diphosphate, UMP = uridine mono-
phosphate, DAP = 2,6-diaminopimelic acid.
[a] Dr. G. Niro, S. C. Weck, Prof. Dr. C. Ducho
Department of Pharmacy, Pharmaceutical and Medicinal Chemistry
Saarland University
Campus C2 3, 66123 Saarbrecken (Germany)
E-mail : christian.ducho@uni-saarland.de
Supporting information and the ORCID identification number(s) for the
author(s) of this article can be found under :
https ://doi.org/10.1002/chem.202003387.
T 2020 The Authors. Published by Wiley-VCH GmbH. This is an open access
article under the terms of the Creative Commons Attribution Non-Commer-
cial NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and
no modifications or adaptations are made.




Recently, additional muraymycins were isolated from the same
producing strain.[5b] In general, muraymycins consist of a
(5’S,6’S)-glycyluridine (’GlyU’) moiety, which is attached to a
urea peptide chain via an aminopropyl linker. The peptide
moiety consists of an l-leucine derivative, the non-proteino-
genic amino acid l-epicapreomycidine (as a cyclic arginine de-
rivative), and a urea-linked l-valine unit (Figure 1). With respect
to their detailed structural features, muraymycins are divided
into four series (A–D). Series A–C contain a non-proteinogenic
(3S)-3-hydroxy-l-leucine unit that is acylated with fatty acid
moieties in the case of series A and B. Where congeners of
series A contain w-functionalized fatty acyl structures (e.g. , A1
4 and A5 5, Figure 1), derivatives of series B possess unfunc-
tionalized, branched fatty acyl chains of different lengths (e.g. ,
B8 6, Figure 1). The C series contains non-acylated (3S)-3-hy-
droxy-l-leucine, and the D series proteinogenic l-leucine. Un-
usual structural motifs, such as the 5’-O-aminoribosylated gly-
cyluridine (GlyU) unit and the non-proteinogenic amino acids
(3S)-3-hydroxy-l-leucine and l-epicapreomycidine, make the
total synthesis of muraymycins challenging. However, the total
synthesis of naturally occurring muraymycins of the D series
has been reported by Ichikawa and Matsuda as well as by
Kurosu and co-workers.[8] Further synthetic routes towards sev-
eral building blocks of muraymycins have also been devel-
oped.[9]
We have established the synthesis of structurally simplified
5’-defunctionalized (’5’-deoxy’) muraymycin analogs (e.g. , the
5’-deoxy congener 9 of muraymycin C4 7, Figure 1).[10] Synthet-
ic analog 9 was found to be a rather potent inhibitor of MraY
in vitro (IC50 = 95:19 nm), although the aminoribose unit is
known to mediate a key interaction with the target enzyme
(see below).[11] The 5’-defunctionalized version of the GlyU core
unit is synthetically more easily accessible,[12] thus making such
5’-deoxy analogs reasonable tools for structure–activity rela-
tionship (SAR) studies.[13] Further SAR investigations have been
conducted on aminoribosylated muraymycin analogs[14a,b] as
well as on structurally more distinct muraymycin-inspired de-
rivatives.[14c]
Mureidomycins, sansanmycins, and related classes contain a
3’-deoxyuridine-derived core moiety, which is attached (via a
remarkable enamide linkage) to a non-proteinogenic (2S,3S)-2-
amino-3-methylaminobutyric acid (AMBA) unit. The AMBA
structure then effectively branches the peptide chain (Fig-
ure 2).[5c, d, 15] In position R4, the aromatic side chains of amino
acids such as tryptophan (e.g. , 12 and 13) or non-proteinogen-
ic m-tyrosine (e.g. , 10, 11, and 14) are incorporated. In position
R5, the side chains of hydrophobic amino acids (e.g. , Met, Leu,
or Ala) can be found. In position R6, a m-tyrosine side chain is
present for mureidomycins and sansanmycins, but a methyl
group (i.e. , alanine) is present for pacidamycins (e.g. , 14). In
the case of mureidomycin C 11, an additional glycine unit is at-
tached in position R7.
SAR studies on mureidomycins and related classes have
shown that aromatic amino acids in position R4 (Figure 2) are
required for biological activity, whereas hydrophobic residues
in position R5 are preferred.[16a,b] In position R6, m-tyrosine is fa-
vored, however, sterically less bulky amino acids are tolerated
as well.[16c] It has also been shown that the (2S,3S)-configura-
tion of the AMBA moiety as well as the native l-configuration
of all other amino acid units are crucial for antimicrobial activi-
ty of these MraY inhibitors.[16c,d] These observed trends are
mainly based on MIC values against P. aeruginosa or M. tubercu-
losis though. It is therefore unclear if the lack of antimicrobial
activity for other analogs might be a result of impaired MraY
inhibition, hampered cellular uptake, or increased cellular
efflux (as the active site of MraY is located at the cytosolic face
of the membrane). A very recent SAR study on mureidomycin
analogs also included some first insights into their selective
cellular uptake into P. aeruginosa.[16e]
Following the first X-ray crystal structure of ligand-free MraY
(from the extremophile Aquifex aeolicus),[17] Lee and co-workers
reported the first X-ray co-crystal structure of MraY (again from
Aquifex aeolicus) in complex with the inhibitor muraymycin D2
Figure 1. Selected examples of naturally occurring muraymycins (4–8) as
well as the synthetic 5’-deoxy analog 9 of muraymycin C4 7.
Figure 2. Selected examples of naturally occurring mureidomycins (10, 11),
sansanmycins (12, 13), and pacidamycins (14). Three letter codes of amino
acids in parentheses refer to the side chain of the respective amino acid.




8.[11a, b] A comparison with the X-ray crystal structure of the
ligand-free apoprotein[17] revealed significant conformational
changes upon inhibitor binding. Two defined binding pockets
for the uracil and the 5’-aminoribose moieties were identified,
whereas the peptide unit is positioned on the surface of the
protein. Recently, Lee and colleagues reported an even more
detailed and comprehensive binding model for the inhibition
of MraY by several nucleoside antibiotics, based on a range of
X-ray co-crystal structures.[11c] Thereby, they identified common
binding sites addressed by multiple sub-classes of nucleoside
antibiotics as well as unique sites for the binding of some sub-
classes, all on the cytosolic side of MraY. Interestingly, the m-ty-
rosine moiety of mureidomycins was found to bind to the
same pocket as the 5’-aminoribose moiety in the case of mur-
aymycins (and related caprazamycins).[11c]
This recent comprehensive study on MraY inhibition by dif-
ferent types of nucleoside antibiotics strongly suggests that it
might be possible to generate novel scaffolds for MraY inhibi-
tors in a modular fashion. Thus, it might be assumed that, for
instance, the nucleoside unit of one sub-class can be com-
bined with the peptide unit of a different sub-class to generate
a “hybrid” MraY inhibitor. This strategy might not only furnish
new lead structures for antibacterial drug development, but it
might also be useful to elucidate the selectivity in the antibac-
terial action of different sub-classes of nucleoside antibiotics.
Based on these considerations, we have designed such an un-
precedented hybrid structure, 15 (Scheme 2).
Target compound 15 contains the 5’-defunctionalized (’5’-
deoxy’) version of the GlyU core unit of muraymycins (like mur-
aymycin analog 9, highlighted in Scheme 2 in blue) and the
peptide moiety of sansanmycin B 13 (highlighted in Scheme 2
in green, also see Figures 1 and 2). It should be noted that
muraymycins usually show activity against Gram-positive bac-
teria, but not against the Gram-negative ESKAPE pathogen
P. aeruginosa. On the other hand, sansanmycin B 13 exhibits
anti-Pseudomonas activity (MIC: 4–16 mg mL@1).[18] Overall,
hybrid structure 15 is therefore potentially useful for the fol-
lowing purposes: (i) to test the aforementioned hypothesis if
structural features of different sub-classes of nucleoside antibi-
otics can be combined in a modular fashion to furnish novel
MraY inhibitors (i.e. , as a ’proof-of-principle’) ; (ii) to test if the
presence of structural features of one particular sub-class with
activity against a particular pathogen might also make the
overall hybrid structure active against that pathogen. In the
case of 15, this would mean that the presence of the sansan-
mycin peptide unit might potentially confer anti-Pseudomonas
activity of 15, in spite of the non-activity of muraymycins
against Pseudomonas. In this work, we report the synthesis of
novel hybrid structure 15 as well as its biological evaluation.
Results and Discussion
Synthesis
For the synthesis of hybrid structure 15, we aimed for a modu-
lar approach that would also enable potential further structural
variations in future studies. Therefore, it was envisioned to
construct 15 from four individual building blocks 16–19
(Scheme 2). After the connection of all four building blocks to-
wards the complete scaffold, a single global deprotection step
under acidic conditions should then furnish target compound
15.[8a, 10, 14]
For the synthesis of the protected nucleosyl amino acid
building block 17, we employed our previously reported proto-
col consisting of six steps starting from uridine (reactions not
shown).[12b] The orthogonally protected version 16 of non-pro-
teinogenic (2S,3S)-2-amino-3-methylaminobutyric acid (AMBA)
was required to prepare the sansanmycin-derived “branched”
peptide structure of the target compound. Building block 16
was therefore synthesized via a modified version of the route
originally reported by Hennings and Williams (Scheme 3).[19]
First, stereoselective Sharpless aminohydroxylation of tert-
butyl crotonate 20 (based on an established procedure[20]) was
used to generate syn-configured amino alcohol 21 in 51 %
yield (Scheme 3). In principle, the determination of the abso-
lute stereochemistry of 21 by using Mosher ester methodology
has been reported before as well.[20] However, we now report
full analytical data of the corresponding products. Therefore,
both enantiomers of amino alcohol 21 were synthesized, ana-
lyzed by chiral HPLC, and transformed to the corresponding
Mosher esters. The stereochemistry was then assigned based
on 1H NMR data (see the Supporting Information for a full de-
scription of this procedure). Subsequently, the hydroxy group
of 21 was silyl-protected to give silyl ether 22 in 87 % yield.
Methylation of the carbamate nitrogen was conducted as re-
ported,[19] even though a mixture of methylated silyl ether and
the desilylated compound 23 was obtained. Therefore, the
subsequent acidic desilylation step was carried out using this
Scheme 2. Hybrid target structure 15, designed based on 5’-defunctional-
ized muraymycin analogs (blue moiety) and sansanmycin B (green moiety),
as well as retrosynthetic considerations for its preparation.




mixture to furnish the desired alcohol 23 in 89 % yield over
two steps from 22. Azide 24 was then synthesized by nucleo-
philic substitution at the 2-position (after transformation of 23
into its mesylate) based on an established protocol.[19] Howev-
er, the product (54 % overall yield over two steps from 23) was
unexpectedly obtained as an epimeric mixture with varying
diastereomeric ratios (d.r. 98:2 to 88:12), eventually owing to a
partially occurring SNi mechanism. The epimeric mixture of
azide 24 was not separated, but reduced under Staudinger
conditions, and the resultant amine was directly allyloxycar-
bonyl-(Alloc)-protected. At this stage, chromatographic separa-
tion of the epimers was feasible and the desired (2S)-epimer,
that is, anti-isomer 25 b, was obtained in 88 % yield. Acidic
cleavage of the tert-butyl ester then afforded the desired ste-
reoisomerically pure building block 16 in quantitative yield
(Scheme 3).
For the synthesis of the urea dipeptide unit, commercially
available Boc-protected tryptophan tert-butyl ester 26 was
transformed into the corresponding isocyanate 27 by using tri-
phosgene under basic conditions (Scheme 4). The highly reac-
tive isocyanate 27 was not purified, but directly converted into
the corresponding urea dipeptide by the addition of a second
amino acid. This procedure avoided epimerization reactions
and thus furnished the resultant urea dipeptide products in
stereoisomerically pure form. In a first attempt, unprotected l-
leucine was used as the second amino acid, but only poor
yields (i.e. , 12 %) of the desired building block 18 were ach-
ieved, most likely owing to solubility issues. To overcome this
hurdle, the 2-(trimethylsilyl)ethyl (TMSE) ester of l-leucine was
used as the second amino acid instead. This variant afforded
urea dipeptide TMSE ester 28 in an improved yield of 52 %.
The l-leucine TMSE ester had been synthesized as reported
before.[21] Subsequent cleavage of the TMSE ester by using
tetra-n-butylammonium fluoride (TBAF) for desilylation fur-
nished the desired building block 18 in quantitative yield
(Scheme 4). Hence, the two-step route via the TMSE ester inter-
mediate 28 was found to be superior to the one-step transfor-
mation into 18 by using unprotected l-leucine. The last re-
quired building block 19 was synthesized by TBDMS-protec-
tion of commercially available N-Boc-protected m-tyrosine 29
under standard conditions, affording product 19 in 86 % yield
(Scheme 4).
With all building blocks 16–19 in hand, the full-length scaf-
fold of target structure 15 was constructed in a stepwise
manner (Scheme 5). The AMBA-derived building block 16 was
attached to the 5’-deoxy nucleosyl amino acid 17 by standard
amide coupling using EDCI and HOAt for activation.[16b] The de-
sired coupling product was obtained in 94 % yield and subse-
quently submitted to Alloc cleavage under usual Pd-catalyzed
conditions.[22] The resultant amine 30 was isolated in 73 % yield
(69 % over two steps from 17). The urea dipeptide moiety was
attached next, by using building block 18 and PyBOP as a cou-
pling reagent. The reaction was carefully monitored by LC-MS
analysis. The desired product 31 was then obtained in 64 %
Scheme 3. Synthesis of the orthogonally protected (2S,3S)-2-amino-3-methylaminobutyric acid (AMBA) building block 16.
Scheme 4. Synthesis of the urea dipeptide building block 18 and of the pro-
tected m-tyrosine building block 19.




yield after aqueous workup and chromatographic purification.
Finally, the secondary amine was Cbz-deprotected under trans-
fer hydrogenation conditions (1,4-cyclohexadiene and Pd black
in iso-propanol) to avoid unwanted reduction of the uracil C5-
C6 double bond.[12b, 13b] The identity of the obtained product
was confirmed by LC-MS analysis only, and the secondary
amine was directly submitted to a final amide coupling with
the m-tyrosine building block 19. This reaction was hampered
owing to steric hindrance of the secondary amine, and its con-
version was closely monitored by LC-MS analysis. However, an
excess of the carboxylic acid 19, HATU and DIPEA was used,
and with elongated reaction time and slightly elevated tem-
perature, the coupling product was finally obtained. This fully
protected derivative of the hybrid structure 15 was not charac-
terized, but directly submitted to acidic global deprotection by
using aqueous trifluoroacetic acid. Target compound 15 was
isolated (after purification by semi-preparative HPLC) in 13 %
yield over the three final steps from intermediate 31
(Scheme 5).
Synthetic key intermediates 18, 30, and 31 were also fully
deprotected under the same acidic conditions, to obtain addi-
tional target compounds 32–34 (in yields of 31–74 %) and to
evaluate their inhibitory potency towards the bacterial target
enzyme MraY (Scheme 6).
Biological evaluation
Target hybrid structure 15 as well as additional target com-
pounds 32–34 were investigated for their in vitro inhibitory
potency against the bacterial enzyme MraY, by using an estab-
lished fluorescence-based assay.[23] As reported before, a crude
membrane preparation of MraY from S. aureus (heterologously
overexpressed in E. coli) was used as source of MraY activi-
ty.[5b, 10, 21, 23] The obtained inhibitory activities (IC50 values) are
listed in Table 1. It cannot totally be ruled out that these inhibi-
tory potencies towards MraY might be different with MraY ho-
Scheme 5. Endgame of the synthesis of target structure 15 : connection of building blocks 16–19 and acidic global deprotection.
Scheme 6. Acidic deprotection of key intermediates 18, 30, and 31 towards
additional target compounds 32–34.




mologs from other bacterial species. However, previous results
strongly suggest that the similarity of different MraY congeners
is quite pronounced and that differences in IC50 values are
much more dependent on the choice of MraY preparation
(crude membranes vs. solubilized protein) rather than the em-
ployed MraY homolog.[23e]
The full-length muraymycin–sansanmycin hybrid structure
15 showed MraY inhibition in the high-nanomolar range
(IC50 = 0.71:0.17 mm). This proved our general concept that
structural motifs of different sub-classes of nucleoside antibiot-
ics can be combined in a modular fashion to generate a novel
scaffold with inhibitory activity towards MraY as the bacterial
target protein. In comparison, our previously reported synthet-
ic muraymycin analog 9[10, 23e] (see above) had been found to
be an approximately 7-fold more active MraY inhibitor
(Table 1). However, if 15 is interpreted as a “hit” compound
with respect to its novel modular scaffold, this result is actually
rather encouraging, having in mind that 9 closely resembles a
naturally occurring nucleoside antibiotic (i.e. , muraymycin C4
7). Thus, a future structural optimization of 15 might lead to
even more potent MraY inhibitors. Unfortunately, only MIC
values for the inhibition of bacterial growth, but usually no IC50
values for MraY inhibition have been described for most previ-
ously reported sansanmycins and their analogs.[16b, 24] This
makes a comparison of the inhibitory potency of 15 with the
activity of sansanmycins difficult.
Owing to its full-length scaffold, additional analog 34 can be
seen as a congener of 15. It was found to inhibit MraY at low
micromolar concentrations (IC50 = 4.4:0.6 mm), that is, as an
approximately 6-fold weaker inhibitor relative to 15. The addi-
tional target affinity of 15 clearly results from the formal ex-
change of the Cbz protecting group in 34 to the m-tyrosine
unit in 15, hence, from the additional presence of the phenolic
hydroxy group and/or the primary amine. It is quite surprising
that these structural alterations only furnish an approximately
6-fold improvement in activity with respect to Lee’s recently
reported structural model for MraY inhibition.[11c] Based on this
work, one would expect that the primary amine of the m-tyro-
sine moiety in 15 should interact with the so-called “uridine-
adjacent pocket” of MraY, which is also addressed by the ami-
noribose unit of naturally occurring muraymycins. In the case
of muraymycins, the presence of the aminoribose unit leads to
a boost in MraY inhibition.[23e] This suggests that the primary
amine in 15 might not be ideally spatially oriented yet to me-
diate a more pronounced interaction with the uridine-adjacent
pocket. In the case of 3’-hydroxymureidomycin A (i.e. , a 3’-hy-
droxylated analog of 10 with a m-tyrosine unit at the same po-
sition as in 15), hydrogen bonds of the hydroxy group and the
amine of the m-tyrosine moiety with T75 and D265 of MraY
have been observed by X-ray crystallography.[11c] On the other
hand, the fact that 34 also was found to be a reasonably
potent MraY inhibitor further supports our hypothesis that
structural variations on the newly established scaffold of type
15 will be feasible.
Truncated analogs 32 and 33 can be interpreted as frag-
ments of the full-length structure 34. Both 32 and 33 were
found to be very weak MraY inhibitors with in vitro activities in
the low-millimolar range (Table 1). This highlights the relevance
of a connection between the nucleoside unit and the peptide
moiety to the full-length scaffold. On the other hand, it was
fairly remarkable that some residual inhibitory activity towards
MraY could still be detected for both truncated analogs 32
and 33. This suggests that fragment-based approaches for the
development of novel MraY inhibitors might be feasible.
Both full-length muraymycin–sansanmycin hybrid structures
15 and 34 were also tested for their activity as inhibitors of an-
tibacterial growth in cellulo. However, no antibacterial activity
(MIC >50 mg mL@1) was found against Gram-positive S. aureus,
Gram-negative E. coli (efflux-competent DH5a and efflux-defi-
cient DtolC strains), and the Gram-negative ESKAPE pathogen
P. aeruginosa. This might be a result of limited cellular uptake,
in particular as no growth inhibition was observed for the
efflux-deficient E. coli strain DtolC. This result suggests that the
novel scaffold of type 15 will also require structural optimiza-
tion towards improved cellular uptake, even though the proof-
of-principle for the MraY inhibition of such hybrid structures
has been successfully provided. Hence, it cannot be evaluated
yet if the presence of the sansanmycin peptide unit within the
hybrid structure might potentially confer anti-Pseudomonas ac-
tivity. Optimization of 15 towards improved cellular uptake
might include i) decoration with lipophilic moieties;[14, 23e] ii)
conjugation to a siderophore;[25a] iii) functionalization with
basic groups.[25b]
Conclusion
We herein report the synthesis and biological evaluation of the
first artificial hybrid structures of two sub-classes of nucleoside
antibiotics. We have formally combined the 5’-defunctionalized
version of the muraymycin nucleoside unit with the peptide
moiety of sansanmycin B. The synthesis of hybrid structure 15
was accomplished in 1.3 % yield over 14 linear steps, by using
a modular approach involving four building blocks. This modu-
lar route is expected to be useful for future structural varia-
tions on the scaffold of type 15 for more detailed SAR studies.
Hybrid structure 15 was found to be a reasonably potent (i.e. ,
high nanomolar) inhibitor of the bacterial target protein MraY
in vitro, thus furnishing the attempted proof-of-principle that
structural features of different sub-classes of nucleoside antibi-
otics can be combined in a modular fashion to furnish novel
MraY inhibitors. Additionally synthesized full-length analog 34
(as a structurally slightly simplified congener of 15) also inhibit-








[a] MraY from S. aureus, heterologously overexpressed in E. coli, crude
membrane preparation. [b] See ref. [23e] .




ed MraY in vitro. This result supports the hypothesis that fur-
ther structural variations of the hybrid scaffold will be feasible
and can be expected to afford more derivatives of this type
with inhibitory activity towards MraY. More detailed studies on
hybrid structures of type 15 will be required for further SAR in-
sights and optimization of the target interaction, but also to
obtain analogs with antibacterial activity in cellulo (which is
absent yet for both 15 and 34). Overall, we have therefore
demonstrated that the modular generation of novel scaffolds
for MraY inhibitors is feasible, even though it apparently fur-
nishes “hit” compounds rather than elaborated MraY-inhibiting
antibiotics with antibacterial activity in cellulo. The reported ap-
proach to fuse structural features of nucleoside antibiotics into
hybrid scaffolds is therefore expected to potentially provide




All chemicals, starting materials, and reagents were purchased
from standard suppliers and used without further purification. N-
Boc-l-m-tyrosine 29 was purchased from GL Biochem Shanghai.
Building block 17 was synthesized from uridine as reported be-
fore.[12b] Air- and/or water-sensitive reactions were carried out
under nitrogen atmosphere with anhydrous solvents if not indicat-
ed otherwise. Anhydrous solvents were obtained in the following
manner: THF, DMF, and CH2Cl2 were dried with a solvent purifica-
tion system (MBRAUN MB SPS 800). Pyridine and iPrOH were dried
over CaH2 and distilled. All of the thus obtained solvents were
stored over molecular sieves (4 a). All other solvents were of tech-
nical quality and distilled prior to use, and deionized water was
used throughout. The glass equipment was dried by heating in
vacuo prior to use. The nitrogen used was dried by using orange
gel and phosphorus pentoxide. All reactions were monitored by
TLC if not stated otherwise. TLC was performed on aluminium
plates precoated with silica gel 60 F254 (VWR). Visualization of the
spots was carried out by using UV light (254 nm) and/or staining
with VSS TLC stain (4 g vanillin, 25 mL H2SO4 (conc.), 80 mL AcOH,
all dissolved in MeOH (680 mL)) under heating. Rf values are given
to the nearest 0.05. For column chromatography, silica gel 60 (40–
63 mm, 230–400 mesh ASTM, VWR) was used. Preparative centrifu-
gal TLC was carried out with a ChromatotronTM 7924T by T-Squared
Technology, using glass plates coated with silica gel 60 PF254 con-
taining a fluorescent indicator (VWR, thickness depending on the
amount of crude material to be separated, for 50–500 mg: 1 mm
layer). Semipreparative HPLC was performed with a VWR-Hitachi
system equipped with an L-2300 pump, an L-2200 autosampler, an
L-2455 Diode Array Detector (DAD), and a LichroCartTM PurospherTM
RP18e column (5 mm, 10 V 250 mm, VWR). Method 1: eluent A
water (+ 0.1 % TFA), eluent B MeCN (+ 0.1 % TFA); 0–3 min gradient
of B (30–40 %), 3–22 min gradient of B (40–60 %), 22–34 min 60 %
B, 34–37 min gradient of B (60–100 %), 37–39 min 100 % B, 39–
40 min gradient of B (100–30 %), flow 2.5 mL min@1, UV/Vis detector
(254 nm, 260 nm). Method 2: eluent A water (+ 0.1 % TFA), eluent B
MeCN (+ 0.1 % TFA); 0–30 min gradient of B (1–20 %), 30–34 min
gradient of B (20–100 %), 34–44 min 100 % B, 44–45 min gradient
of B (100–1 %), flow 2.5 mL min@1, UV/Vis detector (254 nm,
260 nm). Method 3: eluent A water (+ 0.1 % TFA), eluent B MeCN
(+ 0.1 % TFA); 0–8 min gradient of B (20–36 %), 8–32 min 36 % B,
32–38 min gradient of B (36–100 %), 38–44 min 100 % B, 44–45 min
gradient of B (100–20 %), flow 2.5 mL min@1, UV/Vis detector
(254 nm, 260 nm). Method 4: eluent A water (+ 0.1 % TFA), eluent B
MeCN (+ 0.1 % TFA); 0–8 min gradient of B (20–28 %), 8–32 min
28 % B, 32–38 min gradient of B (28–100 %), 38–44 min 100 % B,
44–45 min gradient of B (100–20 %), flow 2.5 mL min@1, UV/Vis de-
tector (254 nm, 260 nm). NMR spectra were recorded by using the
following Bruker NMR spectrometers: for 1H NMR spectra at
500 MHz and 13C NMR spectra at 126 MHz: Avance I 500 with a B
ACS 60 auto sampler, Avance DRX 500 or Avance III 500 with a TCI
cryo probe head; for 19F NMR spectra at 376 MHz: Avance II 400.
For the assignment of signals, 1H,1H-COSY, 1H,13C-HSQC, and 1H,13C-
HMBC spectra were used. In the case of low signal-to-noise ratios,
some chemical shifts were derived from those 2D spectra. All 13C
and 19F NMR spectra are 1H-decoupled. All spectra were recorded
at room temperature if not indicated otherwise and were refer-
enced internally to solvent residual signals wherever possible.
Chemical shifts (d) are quoted in ppm and coupling constants (J)
are reported in Hz. * Indicates additional NMR signals from N-me-
thylated compounds that formed rotamers (marked wherever pos-
sible). § Indicates that NMR data are given for the major rotamer. In
these cases, NMR measurements at high temperatures were not
feasible owing to decomposition of the compound at elevated
temperatures. Low-resolution mass spectra were recorded with a
liquid chromatography coupled mass spectrometer (LC-MS) Survey-
or MSQ Plus from Finnigan. For the LC separation prior to detec-
tion, a NucleodurTM 100-5 C18 column (5 mm, 3 V 125 mm) was used.
High-resolution mass spectra were recorded with a Thermo Scien-
tific Q Exactive Orbitrap mass spectrometer with ESI ionization
mode coupled with an Ultimate 3000 HPLC system by Thermo Sci-
entific, equipped with a Thermo AccucoreTM phenyl-X column
(2.1 mm, 3 V 100 mm). UV spectroscopy was carried out with an Agi-
lent Cary 100 spectrophotometer. Absorption maxima of HPLC-pu-
rified compounds were determined from DAD data. Infrared spec-
troscopy of pure compounds was performed with a Bruker Fourier
transform infrared (FTIR) spectrometer ALPHA with an integrated
PlatiniumATRTM unit. Specific optical rotations were determined by
using a P3000 polarimeter by Kress (l= 589 nm) in the indicated
solvents at room temperature.
Target hybrid structure (15)
To a solution of 31 (20 mg, 15 mmol) in iPrOH (2.0 mL), Pd black
(spatula tip) and 1,4-cyclohexadiene (0.14 mL, 0.15 mmol) were
added. The resultant suspension was stirred under nitrogen atmos-
phere at room temperature for 5 h. After full conversion had been
observed by TLC, the mixture was filtered through a syringe filter,
which was then washed with EtOAc. The solvent of the combined
filtrates was evaporated under reduced pressure to give the crude
amine, which was used without further purification. Protected l-m-
tyrosine 19 (11 mg, 27 mmol) was dissolved in DMF (2 mL). At 0 8C,
O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluoro-
phosphate (HATU; 12 mg, 32 mmol) was added, the mixture was al-
lowed to warm to room temperature and stirred for a further
15 min. Then, a solution of the crude amine in DMF (3 mL) and
N,N-diisopropylethylamine (DIPEA; 12 mL, 67 mmol) were added.
The reaction mixture was stirred at room temperature for 22 h. As
LC-MS analysis still indicated major amounts of unreacted amine,
additional 19 (11 mg, 27 mmol), DIPEA (12 mL, 67 mmol) and HATU
(9 mg, 24 mmol) were added and the solution was stirred at room
temperature for further 9 h. As the conversion was still incomplete
based on LC-MS analysis, the mixture was heated to 35 8C and
stirred at this temperature for an additional 15 h until full conver-
sion of the amine was observed by LC-MS. Then, EtOAc (30 mL)




was added and the solution was washed with HCl (1 m, 30 mL),
water (5 V 30 mL), and brine (30 mL), dried over Na2SO4, and the
solvent was evaporated under reduced pressure. The resultant
crude product was purified by flash column chromatography
(CH2Cl2/MeOH 98:2). The thus obtained crude fully protected inter-
mediate was analyzed by LC-MS only. It was then dissolved in TFA
and water (4:1, 2.5 mL) and stirred at room temperature for 26 h.
Water (5 mL) was added and the solvent was evaporated by lyo-
philization. The resultant crude product was purified by semi-prep-
arative HPLC (method 4) to give 15 as a slightly yellowish fluffy
solid (2.1 mg, 13 % over 3 steps from 31). 1H NMR (500 MHz,
CD3OD): d= 0.77 (d, J = 6.6 Hz, 3 H, AMBA-H-4), 0.89–0.94 (m, 6 H,
Leu-H-5), 1.41–1.53 (m, 2 H, Leu-H-3), 1.61–1.71 (m, 1 H, Leu-H-4),
2.05–2.14*, 2.15–2.22 (m, 1 H, H-5’a), 2.25–2.33 (m, 1 H, H-5’b), 2.79
(s, 3 H, NCH3), 2.81–2.85 (m, 1 H, m-Tyr-H-3a), 3.11–3.29 (m, 3 H, Trp-
H-3, m-Tyr-H-3b), 3.86–3.95 (m, 1 H, H-3’), 3.95–4.02*, 4.02–4.07 (m,
1 H, H-4’), 4.14–4.17 (m, 3 H, H-2’, AMBA-H-3, Leu-H-2), 4.40 (dd, J =
9.1, 5.3 Hz, 1 H, m-Tyr-H-2), 4.53 (dd, J = 6.9, 4.8 Hz, 1 H, AMBA-H-2),
4.55–4.59 (m, 2 H, H-6’, Trp-H-2), 4.60–4.68* (m, 1 H, H-6’), 5.67*,
5.70 (d, J = 8.1 Hz, 1 H, H-5), 5.71*, 5.75 (d, J = 4.1 Hz, 1 H, H-1’),
6.66–6.68 (m, 1 H, m-Tyr-aryl-H-2), 6.72–6.78 (m, 2 H, m-Tyr-aryl-H-4,
m-Tyr-aryl-H-6), 6.99 (ddd, J = 8.0, 7.4, 1.0 Hz, 1 H, Trp-indole-H-6),
7.06 (dd, J = 8.1, 1.0 Hz, 1 H, Trp-indole-H-5), 7.08*, 7.10 (s, 1 H, Trp-
indole-H-2), 7.18 (dt, J = 7.8, 1.8 Hz, 1 H, m-Tyr-aryl-H-5), 7.29–7.34
(m, 1 H, Trp-indole-H-4), 7.52–7.57 (m, 2 H, H-6, Trp-indole-H-7),
7.60* (d, J = 8.1 Hz, 1 H, H-6) ppm; 13C NMR (126 MHz, CD3OD): d=
13.45, 14.72* (AMBA-C-4), 22.08*, 23.48 (Leu-C-5), 23.48*, 23.56
(Leu-C-5), 25.84 (Leu-C-4), 28.50 (NCH3), 28.83
*, 29.01 (Trp-C-3),
35.67*, 35.77 (C-5’), 37.38 (m-Tyr-C-3), 42.05*, 42.10 (Leu-C-3),
51.06*, 51.33 (C-6’), 53.79*, 53.83 (Leu-C-2), 54.03 (m-Tyr-C-2),
54.63*, 54.80, 55.04, 56.13*, 56.42 (AMBA-C-2, AMBA-C-3, Trp-C-2),
74.70 (C-2’), 74.73 (C-3’), 81.60*, 81.65 (C-4’), 92.20*, 92.47 (C-1’),
102.87*, 102.95 (C-5), 110.52*, 110.61 (Trp-indole-C-3’), 112.20 (Trp-
indole-C-4), 115.85*, 115.90 (m-Tyr-aryl-C-4), 117.42*, 117.50 (m-Tyr-
aryl-C-2), 119.49*, 119.56 (Trp-indole-C-7), 119.84 (Trp-indole-C-6),
121.44*, 121.56 (m-Tyr-aryl-C-6), 122.34*, 122.39 (Trp-indole-C-5),
124.70*, 124.72 (Trp-indole-C-2), 128.91*, 128.98 (Trp-indole-C-3a),
131.32*, 131.39 (m-Tyr-aryl-C-5), 138.00*, 138.04 (Trp-indole-C-7a),
142.90*, 142.97 (C-6), 152.18*, 152.25 (C-2), 159.22*, 159.30 (urea-
C=O), 160.00 (m-Tyr-aryl-C-1’), 162.28*, 162.56 (m-Tyr-aryl-C-3),
166.17*, 166.20 (C-4), 169.99 (AMBA-C-1), 170.24 (C-7’), 171.48
(Leu-C-1), 174.59 (Trp-C-1), 176.28 (C-7’) ppm; 19F NMR (376 MHz,
CD3OD): d=@77.14 (TFA-CF3) ppm; MS (ESI): m/z = 922.71 [M+H]+ ;
HRMS (ESI): calcd for C43H56N9O14 [M+H]
+ 922.3941; found:
922.3930; UV (HPLC, MeCN/H2O): lmax = 219, 266 nm; HPLC
(method 4): tR = 18.8 min.
(2S,3S)-2-(((Allyloxy)carbonyl)amino)-3-(((benzyloxy)carbo-
nyl)(methyl)amino)butanoic acid (16)
A solution of 25 b (152 mg, 0.376 mmol) in trifluoroacetic acid and
water (3:2, 10 mL) was stirred at room temperature for 3 d. The sol-
vent was then evaporated under reduced pressure. The resultant
crude product was purified by flash column chromatography
(CH2Cl2/MeOH, 98:2 + 1 % HCOOH) to give 16 as a highly viscous
colorless oil (131 mg, quant.). [a]20D =@11.6 (c = 0.86, CH2Cl2) ;
1H NMR (500 MHz, C2D2Cl4, 80 8C): d= 1.24 (d, J = 6.9 Hz, 3 H, H-4),
2.83 (s, 3 H, NCH3), 4.40–4.48 (m, 2 H, H-2, H-3), 4.51–4.54 (m, 2 H,
Alloc-H-1), 5.09 (d, J = 12.6 Hz, 1 H, Cbz-H-1a), 5.12 (d, J = 12.6 Hz,
1 H, Cbz-H-1b), 5.15 (dd, J = 10.5, 1.4 Hz, 1 H, Alloc-H-3a), 5.26 (dd,
J = 17.2, 1.4 Hz, 1 H, Alloc-H-3b), 5.46 (brs, 1 H, NH), 5.82–5.91 (m,
1 H, Alloc-H-2), 7.21–7.32 (m, 5 H, aryl-H) ppm; 13C NMR (126 MHz,
C2D2Cl4, 80 8C): d= 14.57 (C-4), 30.03 (NCH3), 53.91 (C-3), 57.03 (C-2),
66.41 (Alloc-C-1), 67.85 (Cbz-C-1), 117.84 (Alloc-C-3), 127.95 (Cbz-C-
3, Cbz-C-7), 128.26 (Cbz-C-5), 128.74 (Cbz-C-4, Cbz-C-6), 132.33
(Alloc-C-2), 136.79 (Cbz-C-2), 155.62 (Alloc-C=O), 156.05 (Cbz-C=O),
172.01 (C-1) ppm; MS (ESI): m/z = 373.14 [M+Na]+ ; HRMS (ESI):
calcd for C17H23N2O6 [M+H]
+ 351.1551; found: 351.1549; IR (ATR):
ñ= 2942, 1691, 1530, 1405, 1322, 1167, 932, 697 cm@1; UV (MeCN):
lmax = 229, 257 nm; TLC (CH2Cl2/MeOH, 98:2 + 1 % HCOOH): Rf =
0.30.
Protected l-trypotophan-l-leucine urea dipeptide (18)
Route 1: Boc-protected tryptophan tert-butyl ester hydrochloride
26 (300 mg, 0.756 mmol) was dissolved in CH2Cl2 and aq. NaHCO3
solution (1:1, 10 mL), cooled to 0 8C and stirred vigorously. Triphos-
gene (76.2 mg, 0.269 mmol) was added in one portion and the
mixture was stirred for 30 min. The aqueous layer was then extract-
ed with CH2Cl2 (3 V 40 mL). The combined organics were dried over
Na2SO4 and the solvent was evaporated under reduced pressure.
The resultant crude isocyanate 27 was directly used in the next re-
action without further purification. To a suspension of l-leucine
(99 mg, 0.76 mmol) in DMF (3 mL), a solution of the crude isocya-
nate 27 in THF (6 mL) was added at room temperature. The reac-
tion mixture was stirred at room temperature for 21 h. Subse-
quently, EtOAc (50 mL) was added and the mixture was washed
with HCl (1 m, 3 V 30 mL), dried over Na2SO4, and the solvent was
evaporated under reduced pressure. The resultant crude product
was purified by preparative centrifugal TLC (CH2Cl2/MeOH gradient)
to give 18 as a white solid (48 mg, 12 % over 2 steps from 26).
Route 2 : A solution of 28 (34 mg, 55 mmol) in THF (3 mL) was
cooled to 08C and stirred at this temperature for 10 min. Then, TBAF
solution (1m in THF, 66 mL, 66 mmol) was added, the reaction mixture
was allowed to warm to room temperature and stirred for 4 h. The
solvent was evaporated under reduced pressure. The resultant crude
product was purified by flash column chromatography (CH2Cl2/MeOH,
98:2!9:1) to give 18 as a white solid (29 mg, quant.). [a]20D = +11.3
(c=0.47, CH2Cl2);
1H NMR (500 MHz, [D6]DMSO): d=0.83 (d, J=3.3 Hz,
3 H, Leu-H-5a), 0.85 (d, J=3.3 Hz, 3H, Leu-H-5b), 1.27 (s, 9 H,
OC(CH3)3), 1.28–1.35 (m, 1 H, Leu-H-3a), 1.45–1.52 (m, 1H, Leu-H-3b),
1.60 (s, 9 H, Boc-OC(CH3)3), 1.63–1.70 (m, 1H, Leu-H-4), 2.96 (d, J=
7.0 Hz, 2 H, Trp-H-3), 4.30 (dd, J=13.1, 8.1 Hz, 1H, Leu-H-2), 4.34 (dd,
J=7.1, 7.0 Hz, 1 H, Trp-H-2), 6.29 (brs, 1 H, Trp-2-NH), 6.71 (brs, 1 H,
Leu-2-NH), 7.23–7.26 (m, 1H, Trp-indole-H-5), 7.28–7.38 (m, 1H, Trp-
indole-H-6), 7.46 (s, 1H, Trp-indole-H-2), 7.60 (d, J=7.5 Hz, 1 H, Trp-
indole-H-4), 8.02 (d, J=8.2 Hz, 1 H, Trp-indole-H-7) ppm; 13C NMR
(126 MHz, [D6]DMSO): d=22.40 (Leu-C-5), 23.30 (Leu-C-5), 24.27 (Leu-
C-4), 27.45, 27.69, (OC(CH3)3, Boc-OC(CH3)3, Leu-C-3), 43.29 (Trp-C-3),
52.92 (Leu-C-2), 53.64 (Trp-C-2), 80.14 (OC(CH3)3), 83.53 (Boc-OC(CH3)3),
114.62 (Trp-indole-C-7), 116.43 (Trp-indole-C-3), 119.35 (Trp-indole-C-5),
122.57 (Trp-indole-C-5), 123.81 (Trp-indole-C-2), 124.36 (Trp-indole-C-
6), 130.23 (Trp-indole-C-3a), 134.64 (Trp-indole-C-7a), 149.01 (Boc-
C=O), 157.22 (urea-C=O), 171.83 (Leu-C-1, Trp-C-1) ppm; MS (ESI): m/z
=518.32 [M+H]+ ; HRMS (ESI): calcd for C27H40N3O7 [M+H]
+ 518.2861;
found: 518.2845; UV (MeCN): lmax =230, 260, 286, 294 nm; IR (ATR):
ñ=3301, 2967, 1730, 1552, 1368, 1255, 1154, 1085, 749 cm@1; TLC
(CH2Cl2/MeOH, 98:2+0.5 % HCOOH): Rf =0.15.
N-Boc-O-(tert-butyldimethylsilyl)-l-m-tyrosine (19)
N-Boc-l-m-tyrosine 29 (200 mg, 0.711 mmol) was dissolved in pyridine
(3 mL). At 08C, imidazole (155 mg, 2.27 mmol) and tert-butyldimethyl-
silyl chloride (TBDMS chloride; 226 mg, 1.50 mmol) were added. The
reaction mixture was allowed to warm to room temperature and
stirred for 48 h. Subsequently, water (40 mL) and EtOAc (40 mL) were
added. The organic layer was washed with brine (2 V 40 mL), dried
over Na2SO4, and the solvent was evaporated under reduced pressure.




The resultant crude product was purified by flash column chromatog-
raphy (CH2Cl2/MeOH, 99:1+1 % HCOOH) to give 19 as a yellowish
foam (242 mg, 86%). [a]20D =@2.1 (c=1.4, CH2Cl2); 1H NMR (300 MHz,
[D6]DMSO): d=0.16 (s, 6 H, SiCH3), 0.94 (s, 9 H, SiC(CH3)3), 1.32 (s, 9 H,
OC(CH3)3), 2.80 (dd, J=13.4, 8.2 Hz, 1 H, H-3a), 3.01 (dd, J=13.4,
4.1 Hz, 1 H, H-3b), 3.87–4.02 (m, 1H, H-2), 6.41 (d, J=6.4 Hz, 1H, NH),
6.63 (d, J=7.9 Hz, 1 H, m-Tyr-aryl-H-4), 6.68 (s, 1 H, m-Tyr-aryl-H-2), 6.80
(d, J=7.7 Hz, 1H, m-Tyr-aryl-H-6), 7.09 (dd, J=7.9, 7.7 Hz, 1 H, m-Tyr-
aryl-H-5) ppm; 13C NMR (76 MHz, CDCl3): d=@4.54 (SiCH3), @4.50
(SiCH3), 17.91 (SiC(CH3)3), 25.59 (SiC(CH3)3), 28.14 (OC(CH3)3), 36.17 (C-
3), 55.02 (C-2), 77.94 (OC(CH3)3), 117.73 (m-Tyr-aryl-C-4), 120.73 (m-Tyr-
aryl-C-2), 122.27 (m-Tyr-aryl-C-6), 129.17 (m-Tyr-aryl-C-5), 139.75 (m-
Tyr-aryl-C-1), 154.85 (Boc-C=O), 155.35 (m-Tyr-aryl-C-3), 173.56 (C-
1) ppm; MS (ESI): m/z=396.21 [M+H]+ ; HRMS (ESI): calcd for
C20H34NO5Si [M+H]
+ 396.2201; found: 396.2228; IR (ATR): ñ=2934,
2858, 1670, 1591, 1441, 1260, 1162, 840, 778 cm@1; UV (MeCN): lmax =
223, 270 nm; TLC (CH2Cl2/MeOH, 97:3+1 % HCOOH): Rf =0.30.
tert-Butyl (2R,3S)-3-(((benzyloxy)carbonyl)amino)-2-hydroxy-
butanoate (21)
Aq. NaOCl solution (5 %, 50 mL, 42 mmol) was cooled to 08C. Under
the exclusion of light and vigorous stirring, tBuOH (4.0 mL,
43 mmol) and acetic acid (2.3 mL, 39 mmol) were added. The resul-
tant mixture was stirred at 08C for 3 min and was then washed with
Na2CO3 solution (20 mL) and water (20 mL) to give crude tert-butyl
hypochlorite as a yellow oil, which was used without purification.
Benzyl carbamate (9.38 g, 62.1 mmol) was dissolved in MeCN
(80 mL) and added to a solution of NaOH (2.44 g, 61.0 mmol) in
water (150 mL). Freshly prepared crude tert-butyl hypochlorite
(6.9 mL, 61 mmol) was added dropwise to this solution at 158C over
30 min. Then, a solution of (DHQ)2PHAL (hydroquinine 1,4-phthalazi-
nediyl diether; 780 mg, 1.00 mmol) and tert-butyl crotonate (3.2 mL,
20 mmol) in MeCN (70 mL) was added. The reaction was started by
the addition of potassium osmate (294 mg, 0.798 mmol) and the re-
sultant green solution was stirred at room temperature for 1.5 h.
The reaction was quenched by the addition of sodium sulfite (20 g)
and further stirred for 45 min. The aqueous layer was extracted with
EtOAc (4 V 100 mL). The combined organics were washed with water
(120 mL) and brine (120 mL), dried over Na2SO4, and the solvent was
evaporated under reduced pressure. The resultant crude product
was purified by flash column chromatography (petroleum ether/
EtOAc, 85:15!8:2). The enantiomeric ratio (e.r.) was determined to
be 94:6 by chiral HPLC (see the Supporting Information) and raised
to e.r.>99:1 by recrystallization (EtOAc/hexane) to give 21 as white
needles (3.11 g, 51%). M.p.: 948C; [a]20D =@3.5 (c =2.0, CH2Cl2) ;
1H NMR (500 MHz, CDCl3): d=1.26 (d, J = 7.0 Hz, 3 H, H-4), 1.44 (s,
9 H, OC(CH3)3), 3.13 (d, J =3.8 Hz, 1 H, OH), 4.00 (dd, J =3.8, 2.1 Hz,
1 H, H-2), 4.26 (ddt, J =9.7, 7.0, 2.1 Hz, 1 H, H-3), 4.99 (d, J =9.7 Hz,
1 H, NH), 5.04 (d, J =12.3 Hz, 1 H, Cbz-H-1a), 5.08 (d, J =12.3 Hz, 1 H,
Cbz-H-1b), 7.27–7.38 (m, 5 H, aryl-H) ppm; 13C NMR (126 MHz, CDCl3):
d= 18.50 (C-4), 27.93 (OC(CH3)3), 49.11 (C-3), 66.76 (Cbz-C-1), 73.43
(OC(CH3)3), 83.72 (C-2), 128.18 (Cbz-C-3, Cbz-C-7), 128.21 (Cbz-C-5),
128.62 (Cbz-C-4, Cbz-C-6), 136.64 (Cbz-C-2), 155.62 (Cbz-C=O),
172.57 (C-1) ppm; MS (ESI): m/z =332.06 [M+Na]+ ; HRMS (ESI): calcd
for C16H23NO5Na [M+Na]
+ 332.1468; found: 332.1448; IR (ATR): ñ=
3366, 2977, 1717, 1512, 1229, 1125, 1052, 736, 696 cm@1; UV (hep-
tane): lmax =207 nm; TLC (petroleum ether/EtOAc, 4:1): Rf =0.20.
tert-Butyl (2R,3S)-3-(((benzyloxy)carbonyl)amino)-2-((tert-bu-
tyldimethylsilyl)oxy)butanoate (22)
To a solution of 21 (1.99 g, 6.43 mmol) in pyridine (40 mL), TBDMS
chloride (1.94 g, 12.9 mmol) and imidazole (569 mg, 8.36 mmol)
were added and the resultant solution was stirred at room temper-
ature for 43 h until the starting material was fully consumed (TLC
monitoring). The solution was concentrated under reduced pres-
sure, then EtOAc was added and the organic layer was washed
with NaHCO3 solution (3 V 120 mL) and brine (120 mL). The organic
layer was dried over Na2SO4 and the solvent was evaporated under
reduced pressure. The resultant crude product was purified by
column chromatography (petroleum ether/EtOAc, 9:1) to give 22
as a colorless oil (2.36 g, 87 %). [a]20D = + 13.8 (c = 3.7, CH2Cl2) ;
1H NMR (500 MHz, CDCl3): d= 0.05 (s, 3 H, SiCH3), 0.10 (s, 3 H, SiCH3),
0.92 (s, 9 H, SiC(CH3)3), 1.20 (d, J = 6.7 Hz, 3 H, H-4), 1.42 (s, 9 H,
OC(CH3)3), 4.05 (d, J = 2.3 Hz, 1 H, H-2), 4.17 (ddq, J = 9.3, 6.7, 2.3 Hz,
1 H, H-3), 5.05 (d, J = 12.3 Hz, 1 H, Cbz-H-1a), 5.08 (d, J = 12.3 Hz,
1 H, Cbz-H-1b), 5.15 (d, J = 9.3 Hz, 1 H, NH), 7.27–7.37 (m, 5 H, aryl-
H) ppm; 13C NMR (126 MHz, CDCl3): d=@5.46 (SiCH3), @4.65
(SiCH3), 18.46 (C-4), 18.48 (SiC(CH3)3), 25.86 (SiC(CH3)3), 28.03
(OC(CH3)3), 50.27 (C-3), 66.70 (Cbz-C-1), 74.90 (OC(CH3)3), 81.81 (C-
2), 128.17 (Cbz-C-5), 128.28 (Cbz-C-3, Cbz-C-7), 128.61 (Cbz-C-4,
Cbz-C-6), 136.75 (Cbz-C-2), 155.71 (Cbz-C=O), 170.92 (C-1) ppm; MS
(ESI): m/z = 446.20 [M+Na]+ ; HRMS (ESI): calcd for C22H38NO5Si
[M+H]+ 424.2514; found: 424.2501; IR (ATR): ñ= 3443, 2930, 2857,
1723, 1500, 1214, 1130, 869, 777 cm@1; UV (CHCl3): lmax = 258 nm;
TLC (petroleum ether/EtOAc, 9:1): Rf = 0.20.
tert-Butyl (2R,3S)-3-(((benzyloxy)carbonyl)(methyl)amino)-2-
hydroxybutanoate (23)
NaH (60 % in mineral oil, 197 mg, 4.90 mmol) was suspended in
THF (70 mL). Then, a solution of 22 (415 mg, 0.980 mmol) in THF
(14 mL) was slowly added at room temperature. The resultant solu-
tion was stirred at room temperature for 2 h before dimethyl sul-
fate (1.0 mL, 10 mmol) was added and the suspension was stirred
for a further 2 d. To quench the reaction, water (50 mL) was added
and the resultant mixture was stirred for 40 min. Brine (75 mL) was
added and the aqueous layer was extracted with EtOAc (3 V
50 mL). The combined organics were dried over Na2SO4 and the
solvent was evaporated under reduced pressure. The resultant
crude product was stirred in TFA and water (1:4, 25 mL) at room
temperature for 3 h. The mixture was extracted with CH2Cl2 (3 V
50 mL), the combined organics were dried over Na2SO4 and the
solvent was evaporated under reduced pressure. The resultant
crude product was purified by flash column chromatography (pe-
troleum ether/EtOAc, 85:15) to give 23 as a colorless oil (280 mg,
89 % over two steps from 22). [a]20D =@4.3 (c = 2.8, CH2Cl2) ; 1H NMR
(500 MHz, C2D2Cl4, 80 8C): d= 1.23 (d, J = 6.7 Hz, 3 H, H-4), 1.39 (s,
9 H, OC(CH3)3), 2.84 (s, 3 H, NCH3), 3.98 (d, J = 6.1 Hz, 1 H, H-2), 4.17
(dq, J = 6.7, 6.1 Hz, 1 H, H-3), 5.06 (d, J = 12.6 Hz, 1 H, Cbz-H-1a),
5.10 (d, J = 12.6 Hz, 1 H, Cbz-H-1b), 7.16–7.36 (m, 5 H, aryl-H) ppm;
13C NMR (126 MHz, C2D2Cl4, 80 8C): d= 14.60 (C-4), 28.19 (OC(CH3)3),
31.36 (NCH3) 54.70 (C-3), 67.39 (Cbz-C-1), 74.56 (C-2), 83.05
(OC(CH3)3), 127.71 (Cbz-C-3, Cbz-C-7), 128.14 (Cbz-C-5), 128.71
(Cbz-C-4, Cbz-C-6), 137.19 (Cbz-C-2), 156.88 (Cbz-C=O), 172.51 (C-
1) ppm; MS (ESI): m/z = 346.17 [M+Na]+ ; HRMS (ESI): calcd for
C17H25NO5Na [M+Na]
+ 346.1625; found: 346.1612; IR (ATR): ñ=
2977, 2938, 1691, 1451, 1399, 1319, 1248, 1141, 1025, 742,
670 cm@1; UV (MeCN): lmax = 216, 257 nm; TLC (petroleum ether/
EtOAc, 7:3): Rf = 0.30.
tert-Butyl (3S)-2-azido-3-(((benzyloxy)carbonyl)(methyl)ami-
no)butanoate (24)
Compound 23 (200 mg, 0.618 mmol) was dissolved in CH2Cl2
(13 mL). At 0 8C, triethylamine (0.19 mL, 1.4 mmol) and methanesul-
fonyl chloride (0.11 mL, 1.4 mmol) were added and the resultant




solution was allowed to warm to room temperature and stirred for
2 h. Subsequently, CH2Cl2 (40 mL) was added. The mixture was
washed with brine (40 mL), dried over Na2SO4, and the solvent was
evaporated under reduced pressure. The resultant crude mesylate
(a colorless oil) was dried in vacuo for 1 h and then used without
further purification. To a solution of the crude mesylate in DMF
(15 mL), sodium azide (100 mg, 1.55 mmol) was added and the re-
sultant solution was stirred at 80 8C for 21 h. The solvent was then
evaporated under reduced pressure. The obtained residue was dis-
solved in EtOAc (30 mL) and the solution was washed with water
(2 V 20 mL) and NaHCO3 solution (20 mL). The organic layer was
dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The resultant crude product was purified by flash column
chromatography (petroleum ether/EtOAc, 86:14) to give 24 (diaste-
reomeric mixture) as a colorless oil (116 mg, 54 % over 2 steps from
23, d.r. 88:12 based on the 1H NMR spectrum). 1H NMR (500 MHz,
C2D2Cl4, 80 8C): d= 1.23 (d, J = 6.9 Hz, 3 H, H-4), 1.42 (s, 9 H,
OC(CH3)3), 2.85 (s, 3 H, NCH3), 3.88 (d, J = 6.8 Hz, 1 H, H-2), 4.38–4.44
(m, 1 H, H-3), 5.10 (s, 2 H, Cbz-H-1), 7.25–7.37 (m, 5 H, aryl-H) ppm;
13C NMR (126 MHz, C2D2Cl4, 80 8C): d= 14.30 (C-4), 28.21 (OC(CH3)3),
30.67 (NCH3), 53.22 (C-3), 65.94 (C-2), 67.52 (Cbz-C-1), 83.50
(OC(CH3)3), 127.93 (Cbz-C-3, Cbz-C-7), 128.32 (Cbz-C-5), 128.75
(Cbz-C-4, Cbz-C-6), 136.98 (Cbz-C-2), 155.98 (Cbz-C=O), 167.85 (C-
1) ppm; MS (ESI): m/z = 371.14 [M+Na]+ ; TLC (petroleum ether/
EtOAc, 4:1): Rf = 0.35.
tert-Butyl (3S)-2-(((allyloxy)carbonyl)amino)-3-(((benzyloxy)-
carbonyl)(methyl)amino)butanoate (25)
To a solution of the diastereomeric mixture of 24 (75 mg,
0.21 mmol) in THF and toluene (1:1, 3 mL), triphenylphosphine
(165 mg, 0.629 mmol) and water (188 mL, 10.5 mmol) were added
and the resultant solution was stirred at 50 8C for 22 h. Subse-
quently, Alloc chloride (45 mL, 0.42 mmol) and NaHCO3 (35 mg,
0.42 mmol) were added and the mixture was stirred at room tem-
perature for a further 20 h. EtOAc (40 mL) was added and the or-
ganic layer was washed with water (30 mL) and brine (30 mL),
dried over Na2SO4, and the solvent was evaporated under reduced
pressure. The resultant crude product was purified by flash column
chromatography (petroleum ether/EtOAc, 4:1) to give (2R,3S)-syn-
isomer 25 a (10 mg, 12 %) as a colorless oil and the desired (2S,3S)-
anti-isomer 25 b (76 mg, 88 %) as a colorless oil. 25 a : 1H NMR
(500 MHz, C2D2Cl4, 80 8C): d= 1.18 (d, J = 6.8 Hz, 3 H, H-4), 1.41 (s,
9 H, OC(CH3)3), 2.77 (s, 3 H, NCH3), 4.16 (dd, J = 9.0, 9.0 Hz, 1 H, H-2),
4.28–4.69 (m, 1 H, H-3), 4.48 (d, J = 5.5 Hz, 2 H, Alloc-H-1), 5.09 (s,
2 H, Cbz-H-1), 5.15 (dd, J = 10.5, 1.3 Hz, 1 H, Alloc-H-3a), 5.23 (dd,
J = 17.2, 1.3 Hz, 1 H, Alloc-H-3b), 5.80–5.88 (m, 1 H, Alloc-H-2), 7.22–
7.37 (m, 5 H, aryl-H) ppm; TLC (petroleum ether/EtOAc, 4:1): Rf =
0.25. 25 b : [a]20D =@8.3 (c = 2.1, CH2Cl2) ; 1H NMR (500 MHz, C2D2Cl4,
80 8C): d= 1.18 (d, J = 6.8 Hz, 3 H, H-4), 1.37 (s, 9 H, OC(CH3)3), 2.80
(s, 3 H, NCH3), 4.29–4.39 (m, 2 H, H-2, H-3), 4.47–4.54 (m, 2 H, Alloc-
H-1), 5.08 (s, 2 H, Cbz-H-1), 5.14–5.19 (m, 1 H, Alloc-H-3a), 5.22–5.29
(m, 1 H, Alloc-H-3b), 5.73–5.91 (m, 1 H, Alloc-H-2), 7.18–7.38 (m, 5 H,
aryl-H) ppm; 13C NMR (126 MHz, C2D2Cl4, 80 8C): d= 14.61 (C-4),
28.14 (OC(CH3)3), 29.76 (brs, NCH3), 53.83 (C-3), 57.88 (C-2), 66.16
(Alloc-C-1), 67.51 (Cbz-C-1), 82.89 (OC(CH3)3), 118.02 (Alloc-C-3),
127.99 (Cbz-C-3, Cbz-C-7), 128.17 (Cbz-C-5), 128.72 (Cbz-C-4, Cbz-C-
6), 133.01 (Alloc-C-2), 137.03 (Cbz-C-2), 155.88 (Alloc-C=O), 156.26
(Cbz-C=O), 170.02 (C-1) ppm; MS (ESI): m/z = 429.04 [M+Na]+ ;
HRMS (ESI): calcd for C21H31N2O6 [M+H]
+ 407.2177; found:
407.2167; IR (ATR): ñ= 3299, 2973, 1724, 1673, 1537, 1447, 1234,
1147, 1034, 996, 760, 591 cm@1; UV (MeCN): lmax = 215, 257 nm; TLC
(petroleum ether/EtOAc, 4:1): Rf = 0.15.
Protected l-trypotophan-l-leucine urea dipeptide TMSE
ester (28)
Boc-protected tryptophan tert-butyl ester hydrochloride 26
(120 mg, 0.302 mmol) was dissolved in CH2Cl2 and aq. NaHCO3 so-
lution (1:1, 10 mL), cooled to 0 8C, and stirred vigorously. Triphos-
gene (40 mg, 0.13 mmol) was added in one portion and the mix-
ture was stirred for 30 min. The aqueous layer was then extracted
with CH2Cl2 (3 V 30 mL). The combined organics were dried over
Na2SO4 and the solvent was evaporated under reduced pressure.
The resultant crude isocyanate 27 was directly used in the next re-
action without further purification. l-Leucine TMSE ester[21] (72 mg,
0.31 mmol) was dissolved in DMF (5 mL) and a solution of the
crude isocyanate 27 in THF (6 mL) was added at room tempera-
ture. The reaction mixture was stirred at room temperature for
18 h. Subsequently, EtOAc (50 mL) was added and the mixture was
washed with HCl (1 m, 3 V 30 mL), dried over Na2SO4, and the sol-
vent was evaporated under reduced pressure. The resultant crude
product was purified by flash column chromatography (petroleum
ether/EtOAc, 92.5:7.5!9:1) to give 28 as a white foam (92 mg,
52 % over 2 steps from 26). [a]20D = + 2.6 (c = 0.43, CH2Cl2) ;
1H NMR
(300 MHz, CDCl3): d= 0.04 (s, 9 H, Si(CH3)3), 0.90 (d, J = 6.3 Hz, 3 H,
Leu-H-5a), 0.92 (d, J = 6.3 Hz, 3 H, Leu-H-5b), 0.96–1.07 (m, 2 H, H-
2’), 1.39 (s, 9 H, OC(CH3)3), 1.41–1.48 (m, 1 H, Leu-H-3a), 1.48–1.60
(m, 1 H, Leu-H-3b), 1.59–1.72 (m, 10 H, H-4, Boc-OC(CH3)3), 3.18 (d,
J = 7.0 Hz, 2 H, Trp-H-3), 4.16–4.26 (m, 2 H, H-1’), 4.43 (ddd, J = 8.9,
8.9, 5.2 Hz, 1 H, Leu-H-2), 4.67–4.78 (m, 2 H, H-2’, Leu-2-NH), 4.99 (d,
J = 7.7 Hz, 1 H, Trp-2-NH), 7.19–7.36 (m, 2 H, Trp-indole-H-5, Trp-
indole-H-6), 7.39 (s, 1 H, Trp-indole-H-2), 7.56–7.61 (m, 1 H, Trp-
indole-H-4), 8.12 (d, J = 7.2 Hz, 1 H, Trp-indole-H-7) ppm; 13C NMR
(126 MHz, CDCl3): d=@1.36 (Si(CH3)3), 17.51 (C-2’), 22.06 (Leu-C-5),
23.04 (Leu-C-5), 24.85 (Leu-C-4), 28.11, 28.34 (OC(CH3)3, Boc-
OC(CH3)3), 28.32 (Trp-C-3), 42.28 (Leu-C-3), 51.89 (Leu-C-2), 54.14
(Trp-C-2), 63.67 (C-1’), 82.34 (OC(CH3)3), 83.60 (Boc-OC(CH3)3), 115.23
(Trp-indole-C-7), 115.73 (Trp-indole-C-3), 119.70 (Trp-indole-C-4),
122.78 (Trp-indole-C-5), 124.27 (Trp-indole-C-2), 124.55 (Trp-indole-
C-6), 131.04 (Trp-indole-C-3a), 135.48 (Trp-indole-C-7a), 149.71 (Boc-
C=O), 156.60 (urea-C=O), 171.52 (Trp-C-1), 174.18 (Leu-C-1) ppm;
MS (ESI): m/z = 618.41 [M+H]+ ; HRMS (ESI): calcd for C32H52N3O7Si
[M+H]+ 618.3569; found: 618.3565; IR (ATR): ñ= 3368, 2959, 1729,
1551, 1370, 1252, 1153, 940, 753 cm@1; UV (MeCN): lmax = 229, 260,
285, 294 nm; TLC (petroleum ether/EtOAc, 9:1): Rf = 0.15.
N-Deprotected AMBA-N-acylated nucleosyl amino acid (30)
To a solution of protected nucleosyl amino acid 17[12b] (170 mg,
0.291 mmol) in a mixture of DMF and THF (1:1, 5 mL), a solution of
protected AMBA derivative 16 (99 mg, 0.28 mmol) in a mixture of
DMF and THF (1:1, 5 mL) and 1-hydroxy-7-azabenzotriazole (HOAt;
193 mg, 1.42 mmol) were added. 1-Ethyl-3-(3-dimethylamino-pro-
pyl)carbodiimide (EDCl; 71 mg, 0.37 mmol) was dissolved in DMF
and THF (1:1, 2 mL) and N-methylmorpholine (NMM; 40 mL,
0.37 mmol) was added. After stirring at room temperature for
10 min, this solution was added dropwise to the aforementioned
solution and the resultant reaction mixture was stirred at room
temperature for 27 h. Subsequently, EtOAc (150 mL) was added
and the mixture was washed with HCl (1 m, 50 mL), NaHCO3 solu-
tion (3 V 50 mL), water (50 mL), and brine (50 mL). The organic
layer was dried over Na2SO4 and the solvent was evaporated under
reduced pressure. The resultant crude product was purified by
flash column chromatography (CH2Cl2/MeOH, 98:2) to give the in-
termediate N-Alloc-protected AMBA-N-acylated nucleosyl amino
acid as a white foam (245 mg, 94 %). To a solution of the N-Alloc-
protected AMBA-N-acylated nucleosyl amino acid (152 mg,




0.166 mmol) in CH2Cl2 (5 mL), phenylsilane (95 mL, 1.0 mmol) and
tetrakis(triphenyl-phosphine)palladium(0) (19 mg, 17 mmol) were
added under the exclusion of light. The reaction mixture was
stirred at room temperature for 6 h. Subsequently, EtOAc (40 mL)
was added and the mixture was washed with NaHCO3 solution
(40 mL), dried over Na2SO4, and the solvent was evaporated under
reduced pressure. The resultant crude product was purified by
flash column chromatography (CH2Cl2/MeOH, 98:2!95:5!9:1) to
give 30 as a white foam (100 mg, 73 %, 69 % over 2 steps from 17).
[a]20D = + 52.4 (c = 1.0, CH2Cl2) ;
1H NMR§ (500 MHz, CDCl3): d= 0.04
(s, 3 H, SiCH3), 0.04 (s, 3 H, SiCH3), 0.05 (s, 3 H, SiCH3), 0.06 (s, 3 H,
SiCH3), 0.86 (s, 9 H, SiC(CH3)3), 0.87 (s, 9 H, SiC(CH3)3), 1.23 (d, J =
7.3 Hz, 1 H, AMBA-H-4), 1.43 (s, 9 H, OC(CH3)3), 1.85–2.08 (m, 2 H, H-
5’a, H-5’b), 2.90 (s, 3 H, AMBA-NCH3), 3.56–3.59 (m, 1 H, AMBA-H-2),
3.64–3.69 (m, 1 H, H-3’), 4.14–4.21 (m, 2 H, H-4’, AMBA-H-3), 4.40–
4.48 (m, 2 H, H-2’, H-6’), 5.13–5.15 (m, 2 H, Cbz-H-1), 5.39–5.49 (m,
1 H, H-1’), 5.74 (d, J = 8.1 Hz, 1 H, H-5), 7.25–7.38 (m, 5 H, aryl-H),
7.50 (m, 1 H, H-6), 7.65 (d, J = 5.8 Hz, 1 H, NH) ppm; 13C NMR§
(126 MHz, CDCl3): d=@4.72 (SiCH3), @4.67 (SiCH3), @4.48 (SiCH3),
@4.11 (SiCH3), 13.01 (AMBA-C-4), 18.07 (SiC(CH3)3), 18.16 (SiC(CH3)3),
25.90 (SiC(CH3)3), 25.92 (SiC(CH3)3), 28.08 (OC(CH3)3), 32.05 (AMBA-
NCH3), 35.40 (C-5’), 51.89 (C-6’), 56.07 (AMBA-C-3), 58.38 (AMBA-C-
2), 67.47 (Cbz-C-1), 73.78 (C-2’), 75.71 (C-3’), 82.48 (OC(CH3)3, C-4’),
93.88 (C-1’), 102.46 (C-5), 127.94, 128.08, 128.61 (Cbz-C-3–7), 136.85
(Cbz-C-2), 142.01 (C-6), 150.97 (C-2), 157.02 (Cbz-C=O), 163.35 (C-4),
170.80 (C-7’), 172.97 (AMBA-C-1) ppm; MS (ESI): m/z = 834.66
[M+H]+ ; HRMS (ESI): calcd for C40H68N5O10Si2 [M+H]
+ 834.4499;
found: 834.4486; IR (ATR): ñ= 2931, 2857, 1683, 1457, 1255, 1154,
866, 835, 776, 730 cm@1; UV (MeCN): lmax = 260 nm.
Protected intermediate (31)
To a solution of protected urea dipeptide 18 (40 mg, 76 mmol) in
DMF (3 mL), DIPEA (32 mL, 0.18 mmol) and benzotriazol-1-yl-oxytri-
pyrrolidinophosphonium hexafluorophosphate (PyBOP; 58 mg,
0.11 mmol) were added. The resultant solution was stirred at room
temperature for 3 h. Then, a solution of N-deprotected AMBA-N-
acylated nucleosyl amino acid 30 (62 mg, 74 mmol) in DMF (3.5 mL)
was added and the reaction mixture was stirred at room tempera-
ture for a further 17 h. EtOAc (40 mL) was added and the mixture
was washed with HCl (1 m, 30 mL) and brine (30 mL), dried over
Na2SO4, and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by flash column chroma-
tography (CH2Cl2/MeOH, 98:2) to give 31 as a white foam (62 mg,
64 %). Owing to pronounced rotamer formation of the title com-
pound, which resulted in very complex NMR spectra, 31 was ana-
lyzed by LC-MS only. Purity was confirmed based on the UV chro-
matogram of the LC-MS analysis. MS (ESI): m/z = 1334.24 [M+H]+ ;
TLC (CH2Cl2/MeOH, 98:2): Rf = 0.15.
Additional nucleosyl amino acid-AMBA target compound
(32)
N-Deprotected AMBA-N-acylated nucleosyl amino acid 30 (16 mg,
19 mmol) was dissolved in TFA and water (4:1, 2.5 mL). The reaction
mixture was stirred at room temperature for 25 h. Water (5 mL)
was added and the solvent was evaporated by lyophilization. The
resultant crude product was purified by semi-preparative HPLC
(method 2) to give 32 as a white fluffy solid (9.3 mg, 74 %). 1H NMR
(500 MHz, D2O): d= 1.41 (d, J = 6.9 Hz, 3 H, AMBA-H-4), 2.12–2.29
(m, 1 H, H-5’a), 2.30–2.44 (m, 1 H, H-5’b), 2.83*, 2.87 (brs, 3 H,
AMBA-NCH3), 4.02–4.21 (m, 3 H, H-3’, H-4’, AMBA-H-2), 4.36 (dd, J =
5.2, 4.1 Hz, 1 H, H-2’), 4.40–4.52 (m, 1 H, AMBA-H-3), 4.56–4.69 (m,
2 H, H-6’, AMBA-H-3*), 5.06–5.17 (m, 2 H, Cbz-H-1), 5.75–5.83 (m,
1 H, H-1’), 5.87 (d, J = 8.1 Hz, 1 H, H-5), 7.36–7.50 (m, 5 H, aryl-H),
7.63 (d, J = 8.1 Hz, 1 H, H-6) ppm; 13C NMR (126 MHz, D2O): d=
13.65, 14.23* (AMBA-C-4), 29.59*, 30.52 (AMBA-NCH3), 34.04 (C-5’),
50.57 (AMBA-C-3), 52.19*, 53.14 (C-6), 55.32*, 55.61 (AMBA-C-2),
67.98, 68.15* (Cbz-C-1), 72.98 (C-2’), 73.14 (C-3’), 79.82 (C-4’), 90.48
(C-1’), 102.29 (C-5), 116.41 (q, JCF = 291.6 Hz, TFA-CF3), 127.89,
128.26, 128.54, 128.83 (Cbz-C-3–7), 136.15 (Cbz-C-2), 142.05 (C-6),
151.54 (C-2), 157.84 (Cbz-C=O), 163.06 (q, JCF = 35.5 Hz, TFA-C=O),
166.24 (C-4), 173.62, 173.71*, 173.78 (C-7’, C-1’’) ppm; 19F NMR
(376 MHz, D2O): d=@75.56 (TFA-CF3) ppm; HRMS (ESI): calcd for
C24H32N5O10 [M+H]
+ 550.2144; found: 550.2126; IR (ATR): ñ= 1669,
1542, 1401, 1190, 1133, 808, 724, 557 cm@1; UV (HPLC, MeCN/H2O):
lmax = 216, 261 nm; HPLC (method 2): tR = 16.0 min.
Additional urea dipeptide target compound (33)
Protected urea dipeptide 18 (11 mg, 22 mmol) was dissolved in TFA
and water (4:1, 2.5 mL). The reaction mixture was stirred at room
temperature for 26 h. Water (5 mL) was added and the solvent was
evaporated by lyophilization. The resultant crude product was puri-
fied by semi-preparative HPLC (method 1) to give 33 as a yellowish
fluffy solid (4.1 mg, 51 %). 1H NMR (500 MHz, CD3OD): d= 0.93 (d,
J = 6.4 Hz, 3 H, Leu-H-5a), 0.95 (d, J = 6.6 Hz, 3 H, Leu-H-5b), 1.50
(ddd, J = 13.7, 9.8, 5.5 Hz, 1 H, Leu-H-3a), 1.58 (ddd, J = 13.7, 8.7,
5.0 Hz, 1 H, Leu-H-3b), 1.67–1.78 (m, 1 H, Leu-H-4), 3.23 (ddd, J =
14.7, 5.9, 0.6 Hz, 1 H, Trp-H-3a), 3.23 (ddd, J = 14.7, 5.6, 0.6 Hz, 1 H,
Trp-H-3b), 4.28 (dd, J = 9.8, 5.0 Hz, 1 H, Leu-H-2), 4.61 (dd, J = 5.8,
5.6 Hz, 1 H, Trp-H-2), 7.00 (ddd, J = 8.0, 7.0, 1.0 Hz, 1 H, Trp-indole-
H-6), 7.00 (ddd, J = 8.1, 7.0, 1.1 Hz, 1 H, Trp-indole-H-5), 7.12 (s, 1 H,
Trp-indole-H-2), 7.31 (ddd, J = 8.1, 8.0, 1.0 Hz, 1 H, Trp-indole-H-4),
7.58–7.60 (m, 1 H, Trp-indole-H-7) ppm; 13C NMR (126 MHz, CD3OD):
d= 22.01 (Leu-C-5a), 23.39 (Leu-C-5b), 25.93 (Leu-C-4), 29.07 (Trp-C-
3), 42.49 (Leu-C-3), 52.65 (Leu-C-2), 54.95 (Trp-C-2), 110.57 (Trp-
indole-C-3), 112.07 (Trp-indole-C-4), 119.63 (Trp-indole-C-7), 119.80
(Trp-indole-C-6), 122.28 (Trp-indole-C-5), 124.71 (Trp-indole-C-2),
129.09 (Trp-indole-C-3a), 137.99 (Trp-indole-C-7a), 159.98 (urea-
C=O), 176.10 (Trp-C-1), 177.27 (Leu-C-1) ppm; MS (ESI): m/z =
362.15 [M+H]+ ; HRMS (ESI): calcd for C18H24N3O5 [M+H]
+ 362.1710;
found: 362.1703; IR (ATR): ñ= 3380, 2958, 1640, 1556, 1449, 1192,
746 cm@1; UV (HPLC, MeCN/H2O): lmax = 221, 280 nm; HPLC
(method 1): tR = 16.0 min.
Additional full-length target compound (34)
Protected intermediate 31 (20 mg, 15 mmol) was dissolved in TFA
and water (4:1, 2.5 mL). The reaction mixture was stirred at room
temperature for 42 h. Water (6 mL) was added and the solvent was
evaporated by lyophilization. The resultant crude product was puri-
fied by semi-preparative HPLC (method 3) to give 34 as a white
fluffy solid (4.3 mg, 31 %). 1H NMR (500 MHz, CD3OD): d= 0.91 (d,
J = 6.6 Hz, 3 H, Leu-H-5a), 0.95 (d, J = 6.9 Hz, 3 H, Leu-H-5b), 1.13*,
1.18 (d, J = 6.8 Hz, 3 H, AMBA-H-4), 1.42–1.49 (m, 1 H, Leu-H-3a),
1.50–1.57 (m, 1 H, Leu-H-3b), 1.61–1.72 (m, 1 H, Leu-H-4), 2.06–2.16
(m, 1 H, H-5’a), 2.23–2.31 (m, 1 H, H-5’b), 2.83 (s, 3 H, NCH3), 3.19
(dd, J = 14.8, 6.7 Hz, 1 H, Trp-H-3a), 3.27 (dd, J = 14.8, 5.1 Hz, 1 H,
Trp-H-3b), 3.88 (dd, J = 5.5, 5.1 Hz, 1 H, H-3’), 4.00–4.08 (m, 1 H, H-
4’), 4.10 (dd, J = 4.8, 4.8 Hz, 1 H, H-2’), 4.21 (dd, J = 9.8, 4.8 Hz, 1 H,
Leu-H-2), 4.34–4.43, 4.46–4.55* (m, 1 H, AMBA-H-3), 4.56–4.65 (m,
2 H, H-6’, Trp-H-2), 4.66–4.72 (m, 1 H, AMBA-H-2), 5.06 (d, J =
12.4 Hz, 1 H, Cbz-H-1a), 5.10 (d, J = 12.4 Hz, 1 H, Cbz-H-1b), 5.68 (d,
J = 8.1 Hz, 1 H, H-5), 5.78 (d, J = 4.8 Hz, 1 H, H-1’), 7.00 (ddd, J = 8.0,
7.0, 1.0 Hz, 1 H, Trp-indole-H-6), 7.03–7.08 (m, 1 H, Trp-indole-H-5),
7.11*, 7.13 (s, 1 H, Trp-indole-H-2), 7.23–7.42 (m, 6 H, Cbz-aryl-H,
Trp-indole-H-4), 7.56 (d, J = 8.0 Hz, 1 H, Trp-indole-H-7), 7.60 (d, J =




8.1 Hz, 1 H, H-6), 8.08–8.17 (m, 1 H, 6’-NH or Trp-NH), 8.21–8.30 (m,
1 H, AMBA-NH) ppm; 13C NMR (126 MHz, CD3OD): d= 14.42, 14.96
*
(AMBA-C-4), 22.02 (Leu-C-5), 23.53 (Leu-C-5), 25.85 (Leu-C-4), 29.02
(Trp-C-3), 30.75 (NCH3), 36.02 (C-5’), 42.17 (Leu-C-3), 50.96 (Trp-C-2),
53.87 (Leu-C-2), 54.86 (C-6’), 54.86*, 54.93 (AMBA-C-3), 56.92
(AMBA-C-2), 68.37 (Cbz-C-1), 74.59 (C-2’), 74.88 (C-3’), 81.74 (C-4’),
91.74 (C-1’), 102.95 (C-5), 110.63 (Trp-indole-C-3), 112.20 (Trp-
indole-C-4), 119.50 (Trp-indole-C-7), 119.83 (Trp-indole-C-6), 122.34
(Trp-indole-C-5), 124.77 (Trp-indole-C-2), 128.66, 128.91, 128.98
(Cbz-C-3–7), 129.49 (Trp-indole-C-3a), 137.99 (Trp-indole-C-7a),
138.18 (Cbz-C-2), 142.76 (C-6), 152.25 (C-2), 158.15 (Cbz-C=O),
159.89 (urea-C=O), 166.14 (C-4), 171.49 (AMBA-C-1), 174.10 (C-7’),
175.91 (Trp-C-1), 176.22 (Leu-C-1) ppm; HRMS (ESI): calcd for
C42H53N8O14 [M+H]
+ 893.3676; found: 893.3659; IR (ATR): ñ= 2955,
1663, 1549, 1456, 1192, 1129, 745 cm@1; UV (HPLC, MeCN/H2O):
lmax = 220, 260 nm; HPLC (method 3): tR = 28.5 min.
MraY assay
The overexpression of MraY and the fluorescence-based assay for
MraY activity were performed as described before.[23d, e] In brief, a
crude membrane preparation of MraY from S. aureus (1 mL, final
overall protein concentration ~1 mg mL@1)[23d, e] was added to a
mixture of undecaprenyl phosphate (50 mm), dansylated Park’s nu-
cleotide (7.5 mm),[23d] and the tested compound in buffer (100 mm
Tris-HCl buffer pH 7.5, 200 mm KCl, 10 mm MgCl2, 0.1 % Triton X-
100, 20 mL overall). Fluorescence of the assay mixtures was mea-
sured over time (plate reader, 384-well plate format, lex = 355 nm,
lem = 520 nm). MraY activity at a specific inhibitor concentration
was calculated by linear regression (0 to 2 min) and then plotted
against logarithmic inhibitor concentrations (with sigmoidal fit to
obtain IC50 values).
Antibacterial testing
Tests for antibacterial activity were performed as described
before.[10]
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